Calcineurin inhibitors (CNIs) are both the savior and Achilles' heel of kidney transplantation.
Although CNIs have significantly reduced rates of acute rejection, their numerous toxicities …

Hypertension is one of the most common cardiovascular co-morbidities after successful
kidney transplantation. It commonly occurs in patients with other metabolic diseases, such …

Lipid abnormalities are present in 60% to 81% of heart transplant recipients. 28–30
Hyperlipidemia is thought to play a role in the development of CAV, cerebrovascular …

This study aimed to assess the renopreventive effect of enalapril and/or paricalcitol on
streptozotocin (STZ) diabetes-induced nephropathy and to elucidate their mechanisms of …

Abstract Background/Aim: Transforming growth factor-β1 (TGF-β1) is involved in the
pathogenesis of chronic allograft nephropathy after kidney transplantation. The aim of the …

Antihypertensive treatment for kidney transplant recipients - Cross, NB - 2009 | Cochrane
Library Skip to Content Cookies Our site uses cookies to improve your experience. You can …

Elevated arterial blood pressure is common after kidney transplantation and contributes to
shortened patient and allograft survivals and increased fatal and nonfatal cardiovascular …

Hypertension is common among kidney transplant recipients and may result from traditional
risk factors or transplant specific variables, which commonly include donor associated …

Liver allograft recipients are at increased risk of death from cerebrovascular and
cardiovascular disease. We propose the following strategy of risk-reduction, based on …

Background. Hypertension is common after renal transplantation. Angiotensin II type 1
receptor antagonists are a new class of agents that, without the side-effects mediated by …